Comparative Pharmacology
Head-to-head clinical analysis: ASTRAMORPH PF versus ROXYBOND.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASTRAMORPH PF versus ROXYBOND.
ASTRAMORPH PF vs ROXYBOND
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
ROXYBOND is an immediate-release formulation of oxycodone, a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system (CNS), inhibiting ascending pain pathways and altering pain perception and emotional response to pain.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
Immediate-release oral tablets: 5-15 mg every 4-6 hours as needed for pain. Maximum 60 mg/day. For extended-release: 10-20 mg every 12 hours, adjusted based on prior opioid use.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
3.5–6 hours; prolonged in renal impairment, hepatic impairment, or elderly patients, requiring dose adjustment.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Primarily renal (90% as free drug and glucuronide conjugates). Fecal elimination accounts for <10%.
Category C
Category C
Opioid Analgesic
Opioid Analgesic